TY - JOUR
T1 - Growth hormone of Turner's syndrome
T2 - Beneficial effect on adult height
AU - Rosenfeld, R. G.
AU - Attie, K. M.
AU - Frane, J.
AU - Brasel, J. A.
AU - Burstein, S.
AU - Cara, J. F.
AU - Chernausek, S.
AU - Gotlin, R. W.
AU - Kuntze, J.
AU - Lippe, B. M.
AU - Mahoney, C. P.
AU - Moore, W. V.
AU - Saenger, P.
AU - Johanson, A. J.
N1 - Funding Information:
Supported in part by Genentech, Inc., which provided both financial and editorial support (K. M. Attie, J. Frane, J, Kuntze, A. J. Johanson).
Funding Information:
Drs. Rosenfeld, Brasel, and Lippe have been investigators in trials supported by Genentech, Inc. or the Genentech Foundation; Drs. Rosenfeld, Brasel, Cara, Chernausek, Mahoney, Moore, and Saenger have received grants from Genentech or the Genentech Foundation; Drs. Attie, Frane, Johanson and Joyce Kuntz are or have been employees of Genentech, Inc.
PY - 1998
Y1 - 1998
N2 - Objective: To carry out a multicenter, prospective, randomized trial of human growth hormone (GH), alone or in combination with oxandrolone (ox), in patients with Turner's syndrome (TS). Methods: In an initial phase lasting 12 to 24 months, 70 girls with TS, verified by karyotype, were randomly assigned to one of four groups: (1) observation, (2) OX. (3) GH, or (4) GH plus OX. After completion of the first phase, group 3 subjects continued to receive GH only. All other subjects were treated with GH plus OX. Subjects were followed up until attainment of adult height and/or cessation of treatment. Data from this trial were compared with growth characteristics of 25 American historical subjects with TS (matched for age, height, parental target height, and karyotype) who never received either GH or androgens Results: Of the 70 subjects enrolled, 60 completed the clinical trial. The 17 subjects receiving GH alone all completed the trial and reached a height of 150.4 ± 5.5 cm (mean ± SD), 8.4 ± 4.5 cm taller than their mean projected adult height at enrollment (96% confidence interval [CI]: 6.3 to 10.6 cm). The 43 subjects receiving GH plus OX attained a mean height of 152.1 ± 5.9 cm, 10.3 ± 4.7 cm railer than their mean projected adult height (95% CI: 8.9 to 11.7 cm). The historical control subjects had a mean adult height of 144.2 ± 6.0 cm, precisely matching their original projected adult height of 144.2 ± 6.1 cm. Conclusions: GH, either alone or in combination with OX, is capable of stimulating short-term growth and augmenting adult height in girls with TS. With early diagnosis and initiation of treatment adult height of more than 150 cm is a reasonable goal for most girls with TS.
AB - Objective: To carry out a multicenter, prospective, randomized trial of human growth hormone (GH), alone or in combination with oxandrolone (ox), in patients with Turner's syndrome (TS). Methods: In an initial phase lasting 12 to 24 months, 70 girls with TS, verified by karyotype, were randomly assigned to one of four groups: (1) observation, (2) OX. (3) GH, or (4) GH plus OX. After completion of the first phase, group 3 subjects continued to receive GH only. All other subjects were treated with GH plus OX. Subjects were followed up until attainment of adult height and/or cessation of treatment. Data from this trial were compared with growth characteristics of 25 American historical subjects with TS (matched for age, height, parental target height, and karyotype) who never received either GH or androgens Results: Of the 70 subjects enrolled, 60 completed the clinical trial. The 17 subjects receiving GH alone all completed the trial and reached a height of 150.4 ± 5.5 cm (mean ± SD), 8.4 ± 4.5 cm taller than their mean projected adult height at enrollment (96% confidence interval [CI]: 6.3 to 10.6 cm). The 43 subjects receiving GH plus OX attained a mean height of 152.1 ± 5.9 cm, 10.3 ± 4.7 cm railer than their mean projected adult height (95% CI: 8.9 to 11.7 cm). The historical control subjects had a mean adult height of 144.2 ± 6.0 cm, precisely matching their original projected adult height of 144.2 ± 6.1 cm. Conclusions: GH, either alone or in combination with OX, is capable of stimulating short-term growth and augmenting adult height in girls with TS. With early diagnosis and initiation of treatment adult height of more than 150 cm is a reasonable goal for most girls with TS.
UR - http://www.scopus.com/inward/record.url?scp=0031991527&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031991527&partnerID=8YFLogxK
U2 - 10.1016/S0022-3476(98)70452-4
DO - 10.1016/S0022-3476(98)70452-4
M3 - Article
C2 - 9506648
AN - SCOPUS:0031991527
SN - 0022-3476
VL - 132
SP - 319
EP - 324
JO - Journal of Pediatrics
JF - Journal of Pediatrics
IS - 2
ER -